stockrow
Friday 6 November 2026
Export BLRX’s income statement to Excel — free account
BioLineRx Ltd.
BLRX Healthcare Biotechnology
BioLineRx Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 95.9% from fiscal 2024.
- Revenue
- −3.29%
- EPS
- +31.9%
- Free cash flow
- −1,827.7%
- Total debt
- −40.2%
Quarter to June 2026, against a year earlier
1.77
0.09
−4.84%
Follow BLRX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.29 | 9.65 | 7.27 | 9.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.80) | (3.56) | (4.47) | (4.31) | |
P/B ratio |
0.84 | 0.49 | 0.49 | 0.83 | |
Price to Tangible BV |
1.80 | 1.63 | 2.27 | 47.62 | |
EV/Sales |
0.10 | (0.47) | 0.49 | 5.37 | |
EV/EBITDA |
0.00 | 0.06 | 0.00 | 0.00 | |
EV/Operating CF |
(0.10) | 0.07 | (0.09) | (0.69) | |
EV/FCF |
(0.09) | 0.07 | (0.09) | (0.69) | |
Quick Ratio |
1.90 | 1.76 | 1.41 | 1.01 | |
Current Ratio |
2.09 | 1.95 | 1.58 | 1.20 | |
Net Debt/EBITDA |
7.25 | 3.59 | 3.26 | 1.83 | |
Debt/Assets |
25.32% | 21.85% | 20.20% | 20.01% | |
Debt/Equity |
0.52 | 0.38 | 0.38 | 0.40 | |
Asset Turnover |
0.28 | 0.03 | 0.03 | 0.04 | |
Operating CF/Net income |
2.16 | 2.31 | 1.42 | 1.06 | |
Capex/Depreciation |
0.00 | (0.43) | (0.07) | 0.22 | |
Interest Coverage |
(7.26) | (12.09) | (12.02) | (17.18) | |
Research and Development Expense of Revenue |
402.58% | 1,250.00% | 529.98% | 1,001.02% | |
Selling, General and Administrative Expense of Revenue |
194.61% | 574.74% | 179.87% | 294.22% | |
Intangible Assets out of Total Assets |
0.26 | 0.40 | 0.42 | 0.49 | |
Share Based Compensation of Revenue |
23.65% | 24.74% | 16.35% | 26.87% | |
Graham Net Nets |
0.50 | 0.54 | 0.36 | (0.04) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(36.87%) | (6.14%) | (83.48%) | (51.32%) | |
Free Cash Flow Yield |
(82.68%) | (71.28%) | (76.56%) | (78.21%) | |
Revenue per Share |
0.10 | 0.05 | 0.11 | 0.07 | |
Operating CF per Share |
(0.48) | (0.78) | (0.51) | (0.72) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.48) | (0.79) | (0.52) | (0.72) | |
Cash per Share |
5.80 | 5.08 | 3.91 | 2.94 | |
Shareholders Equity per Share |
4.50 | 5.68 | 4.70 | 3.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.50 | 5.68 | 4.70 | 3.74 | |
Free Cash Flow |
(2.11) | (3.23) | (2.29) | (3.20) | |
Working Capital |
14.86 | 11.56 | 7.96 | 2.67 | |
Capital Expenditures |
— | (0.03) | (0.01) | 0.02 | |
Net Current Asset Value |
8.25 | 6.12 | 3.62 | (0.51) | |
EV/EBIT |
0.00 | 0.05 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.14 | 0.01 | (0.06) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.33 | 2.21 | 1.91 | 0.50 | |
Average Payables |
6.83 | 6.98 | 6.80 | 6.37 | |
Average Inventory |
2.86 | 2.65 | 2.74 | 2.51 | |
Average Assets |
46.27 | 39.91 | 41.15 | 38.37 | |
Average Common Equity |
14.02 | 18.40 | 20.85 | 18.35 |
Columns are period end dates · fundamentals updated 26 Oct 2026